Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was us

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ACRV
Bullish
medium confidence
Mentioned
$ACRV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACRVBullishMed
01

Why it matters

The 8-K provides a fresh set of near-term catalysts: acquisition of ACR-525 (Phase 2-ready JAK1 inhibitor) and continued dosing for ACR-368’s Phase 2b registrational-intent trial, with an interim analysis expected in Q4 2026. It also highlights late-breaking early Phase 1/2 data for ACR-2316 at major oncology conferences and reiterates cash of $77.8M as of Sept. 30, 2026 to fund operations into Q4 2027.

02

Market read

Traders can use the filing to update the near-term biotech catalyst calendar (Q4 2026 interim analysis and upcoming conference presentations) and reassess funding runway and pipeline breadth.

03

What to watch

Cash runway is extended to Q4 2027, but dilution risk remains if upcoming trials require additional funding before key interim analyses deliver decisive results.

Relevance 7/10Novelty 7/10Timing: after-hours filing, with catalysts flagged for Q4 2026 and upcoming symposium presentations

Background

Acrivon is a clinical-stage biotech using its Generative AI-driven Phosphoproteomics AP3 platform to guide precision medicine programs across oncology and immunology/inflammation.

Company-level read

Ticker impact

$ACRVBullishMedium confidence
Context

Acrivon filed an 8-K with Q3 2026 results plus pipeline updates, including ACR-525 acquisition and Phase 2b interim analysis timing for ACR-368.

Expected impact

Likely upward bias as investors price in upcoming readouts and the expanded immunology and inflammation pillar, offset by typical biotech binary-trial risk.

Evidence & confidence

The article is a primary SEC filing with multiple time-linked development milestones and cash runway guidance, but it does not provide explicit financial guidance or trial endpoints that would mechanically force a large repricing.

Market effects

Reinforces investor focus on AI-driven precision proteomics platforms and immunology expansion among clinical-stage biotech peers.

Limited, as the event is company-specific and not a macro release.

Low, confined to US-listed biotech sentiment and clinical-trial calendar expectations.

Counterpoint

Despite multiple catalysts, the update is still pre-approval and does not include Phase 2 efficacy readouts or quantified endpoint success, so the market may fade the news if expectations were already high.

Key entities

  • Acrivon Therapeutics, Inc.

    Nasdaq-listed clinical-stage biotech reporting Q3 2026 results and pipeline/business highlights via SEC Form 8-K.

  • ACR-525

    Oral, potentially best-in-class JAK1 inhibitor acquired by Acrivon, targeted for Phase 2 development in eosinophilic esophagitis.

  • ACR-368

    Selective CHK1/2 inhibitor in a Phase 2b registrational-intent trial in all-comer serous endometrial cancer, with interim analysis expected in Q4 2026.

  • ACR-2316

    Oral WEE1/PKMYT1 inhibitor with AP3-predicted tumor activity; late-breaking early Phase 1/2 results planned for major symposium presentation.

Related articles

$ACRVMed

Acrivon Therapeutics, Inc. (ACRV): Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1…

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Regulation FD Disclosure. Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8,

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.